AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36620632 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibacterial prophylaxis (IV ABX) with compliance rates of 96.6% and biologic envelope hydrated in antibiotics (77.1%)
Number of subjects: 1102
Study 36620632 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic envelope hydrated in antibiotics
Number of subjects: 1102
Study 36620632 — intervention group
Group type: COMPARATOR
Intervention: Antibacterial envelopes without adjunct IV ABX
Number of subjects: 1102
Study 36620634 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban administered through PEG at approved doses
Number of subjects: 12
Study 36620646 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stent strategy
Number of subjects: 905
Study 36620646 — intervention group
Group type: EXPERIMENTAL
Intervention: T-stenting
Number of subjects: 905
Study 36620646 — intervention group
Group type: EXPERIMENTAL
Intervention: V-stenting
Number of subjects: 905
Study 36620646 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stent strategy
Number of subjects: 905
Study 36620770 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg/day)
Number of subjects: 130
Study 36620770 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose atorvastatin (not specified)
Number of subjects: 130
Study 36620891 — intervention group
Group type: EXPERIMENTAL
Intervention: Active continuous positive airway pressure
Number of subjects: 30
Study 36620891 — intervention group
Group type: COMPARATOR
Intervention: Sham continuous positive airway pressure
Number of subjects: 30
Study 36620891 — intervention group
Group type: COMPARATOR
Intervention: Comparison of active vs sham
Number of subjects: 30
Study 36620892 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once daily
Number of subjects: 685
Study 36620965 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran (300 mg subcutaneous, twice-yearly)
Number of subjects: 497
Study 36620965 — intervention group
Group type: COMPARATOR
Intervention: Evolocumab (140 mg subcutaneous, every 2 weeks for 360 days, then inclisiran twice-yearly)
Number of subjects: 497
Study 36621000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg on Days 1 and 8 of each 21-day treatment cycle until disease progression/unacceptable toxicity
Number of subjects: 80
Study 36621036 — intervention group
Group type: EXPERIMENTAL
Intervention: Written preparatory information booklet ('The SUMMIT Study: Next Steps')
Number of subjects: 2014
Study 36621142 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous systemic therapies (specifically protein kinase inhibitors)
Number of subjects: 3290
Study 36621145 — intervention group
Group type: EXPERIMENTAL
Intervention: α-linolenic acid (ALA)
Number of subjects: 0
Study 36621145 — intervention group
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid (DHA)
Number of subjects: 0
Study 36621145 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 36621212 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT)
Number of subjects: 29
Study 36621212 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 29
Study 36621265 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognitive and active learning theory-based classroom cooking with tasting lessons, active recess games, cooking with tasting food promotion during school lunch, family nights, and take-home intervention reinforcements; a 7-month program delivered by a trained intervention team.
Number of subjects: 851
Study 36621265 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening events for families.
Number of subjects: 851
Study 36621265 — intervention group
Group type: EXPERIMENTAL
Intervention: Online survey for parents regarding recipe preparation.
Number of subjects: 851
Study 36621265 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home activity sheets for students.
Number of subjects: 851
Study 36621410 — intervention group
Group type: EXPERIMENTAL
Intervention: V114
Number of subjects: 1720
Study 36621410 — intervention group
Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 1720
Study 36621554 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-ingestion of flavan-3-ols and cocoa methylxanthines (theobromine)
Number of subjects: 10
Study 36621554 — intervention group
Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 10
Study 36621554 — intervention group
Group type: COMPARATOR
Intervention: Theobromine
Number of subjects: 10
Study 36621751 — intervention group
Group type: EXPERIMENTAL
Intervention: mt-sDNA second round testing
Number of subjects: 2758
Study 36621751 — intervention group
Group type: COMPARATOR
Intervention: mt-sDNA first round testing
Number of subjects: 2758
Study 36621757 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted lobectomy (RAL)
Number of subjects: 320
Study 36621757 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted lobectomy (VAL)
Number of subjects: 320
Study 36621827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 1028
Study 36621827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1028
Study 36621830 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-1205c monotherapy (200-1200 mg BID) followed by combination therapy with DS-1205c (800 mg BID) and gefitinib (250 mg once daily)
Number of subjects: 20
Study 36621830 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-1205c (800 mg BID) in combination with gefitinib (250 mg once daily)
Number of subjects: 20
Study 36621880 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-informed risk assessment (GIRA) report
Number of subjects: 25000
Study 36621880 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of high-risk GIRA
Number of subjects: 25000
Study 36621880 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated genetic risk assessment
Number of subjects: 25000
Study 36622121 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 218
Study 36622148 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HP and dolutegravir
Number of subjects: 30
Study 36622148 — intervention group
Group type: COMPARATOR
Intervention: 3HP alone
Number of subjects: 30
Study 36622148 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid with neither dolutegravir nor rifapentine
Number of subjects: 30
Study 36622252 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraceptive use
Number of subjects: 0
Study 36622252 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36622402 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (60 mg FTD/TPI, 20 mg tablet, 3 tablets)
Number of subjects: 32
Study 36622402 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Lonsurf)
Number of subjects: 32
Study 36622424 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified surgical anchor placement
Number of subjects: 13
Study 36622458 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient care
Number of subjects: 237
Study 36622458 — intervention group
Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 237
Study 36622462 — intervention group
Group type: COMPARATOR
Intervention: no-basic Therapy Intensity Level (TIL)
Number of subjects: 2320
Study 36622462 — intervention group
Group type: EXPERIMENTAL
Intervention: extreme Therapy Intensity Level (eTIL)
Number of subjects: 2320
Study 36622462 — intervention group
Group type: COMPARATOR
Intervention: mild-moderate Therapy Intensity Level (TIL)
Number of subjects: 2320
Study 36622462 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy Intensity Level (TIL)
Number of subjects: 2320
Study 36622539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecarfarin 10 mg
Number of subjects: 40
Study 36622539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecarfarin 20 mg
Number of subjects: 40
Study 36622539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecarfarin 30 mg
Number of subjects: 40
Study 36622539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecarfarin 40 mg
Number of subjects: 40
Study 36622539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecarfarin (all doses)
Number of subjects: 40
Study 36622552 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI with SAPIEN 3
Number of subjects: 0
Study 36622552 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 0
Study 36622567 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity (WHR ≥ 0.9 in men and WHR ≥ 0.85 in women)
Number of subjects: 394
Study 36622567 — intervention group
Group type: EXPERIMENTAL
Intervention: General obesity (BMI ≥ 30)
Number of subjects: 394
Study 36622653 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered parent-child interaction therapy (iPCIT) for 20 weeks
Number of subjects: 150
Study 36622653 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered parent-child interaction therapy (iPCIT)
Number of subjects: 150
Study 36622653 — intervention group
Group type: COMPARATOR
Intervention: Referrals as usual (RAU)
Number of subjects: 150
Study 36622674 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced pharmacy care with a focus on health-related social needs
Number of subjects: 364
Study 36622674 — intervention group
Group type: COMPARATOR
Intervention: Usual pharmacy care focused on medication adherence
Number of subjects: 364
Study 36622685 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Brain-Computer Interface (BCI)
Number of subjects: 5
Study 36622724 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormonal contraception
Number of subjects: 314704
Study 36622726 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 321
Study 36622726 — intervention group
Group type: COMPARATOR
Intervention: School-as-usual control group
Number of subjects: 321
Study 36622777 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 63
Study 36622777 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 63
Study 36622777 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising controls
Number of subjects: 63
Study 36622798 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PrEP dosing (90 days) followed by 1 to 7 doses/week (90 days)
Number of subjects: 0
Study 36622798 — intervention group
Group type: EXPERIMENTAL
Intervention: edPrEP adherence classification
Number of subjects: 0
Study 36622879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness mobile app intervention
Number of subjects: 0
Study 36622879 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 36622896 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 70
Study 36622896 — intervention group
Group type: COMPARATOR
Intervention: Secondary wound healing
Number of subjects: 70
Study 36622954 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation Rowing Training (FESRT) for 12 weeks, 3 sessions/week at 70-85% of peak heart rate
Number of subjects: 21
Study 36622954 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 21
Study 36623230 — intervention group
Group type: EXPERIMENTAL
Intervention: 70-Gy once-daily radiotherapy
Number of subjects: 638
Study 36623230 — intervention group
Group type: COMPARATOR
Intervention: 45-Gy twice-daily radiotherapy
Number of subjects: 638
Study 36623234 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized body-worn alcohol dispenser
Number of subjects: 40
Study 36623234 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 36623241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg once every 3 weeks for 6 months
Number of subjects: 35
Study 36623241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab for 1 year followed by surveillance without surgical resection
Number of subjects: 35
Study 36623241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab for less than 1 year
Number of subjects: 35
Study 36623241 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 35
Study 36623241 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial immune profiling with imaging mass cytometry
Number of subjects: 35
Study 36623246 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation (WBI)
Number of subjects: 3309
Study 36623246 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy APBI (38.5 Gy/10 fraction twice daily)
Number of subjects: 3309
Study 36623247 — intervention group
Group type: EXPERIMENTAL
Intervention: PAE
Number of subjects: 0
Study 36623247 — intervention group
Group type: EXPERIMENTAL
Intervention: PAE + MD
Number of subjects: 0
Study 36623247 — intervention group
Group type: EXPERIMENTAL
Intervention: PAE + MD + TD
Number of subjects: 0
Study 36623318 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy CT
Number of subjects: 0
Study 36623318 — intervention group
Group type: COMPARATOR
Intervention: Positron emission tomography (PET)
Number of subjects: 0
Study 36623419 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS targeting left sensorimotor cortex (LSMC) during visual attention for 4 weeks
Number of subjects: 40
Study 36623419 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study 36623423 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-density lipoprotein (VLDL)-TG concentrations
Number of subjects: 50
Study 36623423 — intervention group
Group type: EXPERIMENTAL
Intervention: TG within lipoprotein subclasses, particularly VLDL
Number of subjects: 50
Study 36623515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus veliparib
Number of subjects: 320
Study 36623515 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus placebo
Number of subjects: 320
Study 36623517 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (100 U/mL) once daily with mealtime insulin aspart (100 U/mL)
Number of subjects: 225
Study 36623517 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir (100 U/mL) once or twice daily with mealtime insulin aspart (100 U/mL)
Number of subjects: 225
Study 36623641 — intervention group
Group type: EXPERIMENTAL
Intervention: High fasting stress hyperglycemia ratio (SHR)
Number of subjects: 5308
Study 36623641 — intervention group
Group type: COMPARATOR
Intervention: Low fasting stress hyperglycemia ratio (SHR)
Number of subjects: 5308
Study 36623678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 20 mg
Number of subjects: 319
Study 36623678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 70 mg
Number of subjects: 319
Study 36623678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib 200 mg
Number of subjects: 319
Study 36623678 — intervention group
Group type: EXPERIMENTAL
Intervention: Brepocitinib 10 mg
Number of subjects: 319
Study 36623678 — intervention group
Group type: EXPERIMENTAL
Intervention: Brepocitinib 30 mg
Number of subjects: 319
Study 36623678 — intervention group
Group type: EXPERIMENTAL
Intervention: Brepocitinib 60 mg
Number of subjects: 319
Study 36623678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 36623822 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention services
Number of subjects: 404
Study 36623822 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 404
Study 36623839 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis (POLAR) system
Number of subjects: 194
Study 36623839 — intervention group
Group type: COMPARATOR
Intervention: Endoscopists
Number of subjects: 194
Study 36624219 — intervention group
Group type: EXPERIMENTAL
Intervention: LXS196 100-1000 mg once daily (QD), n=38
Number of subjects: 68
Study 36624219 — intervention group
Group type: EXPERIMENTAL
Intervention: LXS196 200-400 mg twice daily (BID), n=30
Number of subjects: 68
Study 36624218 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of ICG-FI (Time to Visibility, Time to Maximum Visibility, Time to Wash-out)
Number of subjects: 55
Study 36624218 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative pixel analysis of ICG-FI
Number of subjects: 55
Study 36624235 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreatoduodenectomy (LPD)
Number of subjects: 76
Study 36624252 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard D-Dimer threshold of 500 ng/mL
Number of subjects: 10837
Study 36624252 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted D-dimer threshold
Number of subjects: 10837
Study 36624252 — intervention group
Group type: COMPARATOR
Intervention: D-dimer testing among SARS-CoV-2 positive patients
Number of subjects: 10837
Study 36624292 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (IPI) at 1 mg/kg and Nivolumab (NIVO) at 3 mg/kg combined with Melphalan Percutaneous Hepatic Perfusion (M-PHP) at 3 mg/kg (maximum of 220 mg) for 12 weeks.
Number of subjects: 7
Study 36624312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal transplantation of human fetal neural precursor cells (hfNPCs)
Number of subjects: 12
Study 36624312 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dosage of hfNPCs
Number of subjects: 12
Study 36624315 — intervention group
Group type: EXPERIMENTAL
Intervention: Afamitresgene autoleucel (afami-cel)
Number of subjects: 38
Study 36624374 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 40
Study 36624374 — intervention group
Group type: COMPARATOR
Intervention: Classical Thoracolumbar Interfascial Plane (TLIP) block
Number of subjects: 40
Study 36624380 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 2904
Study 36624380 — intervention group
Group type: COMPARATOR
Intervention: Point-by-point radiofrequency ablation (RFA)
Number of subjects: 2904
Study 36624384 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia
Number of subjects: 110
Study 36624384 — intervention group
Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 110
Study 36624391 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemsex-associated drug users
Number of subjects: 660
Study 36624391 — intervention group
Group type: COMPARATOR
Intervention: Tobacco, alcohol, and cannabis users
Number of subjects: 660
Study 36624440 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-back method plus routine education sessions
Number of subjects: 258
Study 36624440 — intervention group
Group type: COMPARATOR
Intervention: Routine education sessions (Control)
Number of subjects: 258
Study 36624448 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline (HS)
Number of subjects: 52
Study 36624448 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic saline (NS)
Number of subjects: 52
Study 36624483 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative proton beam therapy
Number of subjects: 25
Study 36624526 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) - 30 mg/kg loading dose, then 1 mg/kg/h for 12 hours
Number of subjects: 244
Study 36624526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline) - identical intravenous administration as bolus and continuous infusion
Number of subjects: 244
Study 36624598 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral vestibular implantation with an investigational multichannel vestibular implant
Number of subjects: 1
Study 36624598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic stimulation targeting individual semicircular canals
Number of subjects: 1
Study 36624598 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous device use (24 h/d except during sleep) for 18 months
Number of subjects: 1
Study 36624727 — intervention group
Group type: EXPERIMENTAL
Intervention: velusetrag 5 mg
Number of subjects: 232
Study 36624727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 36624727 — intervention group
Group type: EXPERIMENTAL
Intervention: velusetrag 30 mg
Number of subjects: 232
Study 36624727 — intervention group
Group type: EXPERIMENTAL
Intervention: velusetrag (all doses)
Number of subjects: 232
Study 36624825 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile activity smartphone app with motivational text messaging
Number of subjects: 103
Study 36624951 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of enriched hen eggs (3 hard-boiled per day for 21 days)
Number of subjects: 34
Study 36624951 — intervention group
Group type: COMPARATOR
Intervention: Regular hen eggs (Control group)
Number of subjects: 34
Study 36625233 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0
Study 36625233 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 36625502 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 45
Study 36625502 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose to the ipsilateral lateral pterygoid muscle above the median value (36.8 grays)
Number of subjects: 45
Study 36625789 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonates (oral and intravenous)
Number of subjects: 385
Study 36625789 — intervention group
Group type: COMPARATOR
Intervention: Oral alendronate
Number of subjects: 385
Study 36625789 — intervention group
Group type: COMPARATOR
Intervention: Intravenous pamidronate
Number of subjects: 385
Study 36625831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogstate computerized battery during chemotherapy and 1-year post-treatment
Number of subjects: 43
Study 36625831 — intervention group
Group type: EXPERIMENTAL
Intervention: Cogstate computerized battery
Number of subjects: 43
Study 36625894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks) plus cabozantinib (40 mg/day)
Number of subjects: 0
Study 36625894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib exposure
Number of subjects: 0
Study 36625894 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline albumin and nivolumab clearance
Number of subjects: 0
Study 36625894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib clearance
Number of subjects: 0
Study 36625894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose modification strategies for cabozantinib
Number of subjects: 0